SpectRx receives more funding from NCI (US National Cancer Institute)
This article was originally published in Clinica
Executive Summary
The US National Cancer Institute (NCI) has granted SpectRx a further $1.1m in funding to support development of the company's noninvasive cervical cancer detection technology. SpectRx had previously received $1.4m from the NCI to settle charges incurred by clinical trials of the diagnostic device.